ESTRO 2020

Session Item

Poster highlights 17 CL : Palliation
Poster Highlights
08:45 - 08:53
Paravertebral Muscle Training in Patients with Unstable Spinal Metastases
Tanja Sprave, Germany


Paravertebral Muscle Training in Patients with Unstable Spinal Metastases
Authors: Tanja Sprave.(Universitaetsklinik Freiburg, RadioOncology, Freiburg, Germany)
Show Affiliations
Purpose or Objective

Isometric paravertebral muscle training (IPMT) may improve mobility, pain, and quality of life (QOL) in cancer patients with spinal metastases. However, this regimen remains unproven in patients with unstable spinal metastases (USM), a population at high risk for clinical exacerbation with such interventions. Thus, we conducted this exploratory, non-blinded, randomized controlled trial (NCT02847754) to evaluate the safety/feasibility of IPMT and secondarily assess pain, bone density, pathologic fracture rate, and QOL.

Material and Methods

 All patients had histologically/radiologically confirmed USM (per Taneichi score) and underwent non-operative management with 5-10 fractions of palliative radiotherapy (RT). Randomization (1:1) groups were IPMT (intervention, INT) or muscle relaxation (control, CON); both lasted 15 minutes/day and started concurrently with radiotherapy. The primary endpoint was feasibility (completion of training programs 3 months post-RT). Secondary endpoints were pain response (Visual Analog Scale) and opioid consumption, bone density and pathologic fracture rate, and QOL (EORTC questionnaires).


Sixty patients were randomized and 56 received protocol therapy. Mean survival in both groups was 4.4 months. There were no adverse events with either training regimen. Altogether, ≥80% of the planned sessions were completed by 55% (n=16/29) in CON and 67% (n=18/27) in INT. Regarding the post-radiotherapy home-based training, ≥80% of planned sessions were completed by 64% (n=9/14) of the INT cohort. There were no differences in pain scores, opioid consumption, or bone density between arms (p>0.05 for all). No difference was observed between groups regarding new pathological fractures (INT: n=1 vs CON: n=3) after 3 months (p=0.419).There were no QOL differences between arms (all parameters p>0.05).


 IPMT is safe and feasible for high-risk USM patients. Future trials adequately powered for relevant endpoints are thus recommended.